- Email: [email protected]
5366861 Immunoassay and reagent kit used therefor
PATENT ABSTRACTS molecular weight sub-unit is in the range of 6.07.0. In addition, the N-terminal amino acid sequence of the two subunits are described. With regard to the purified protein, inhibin, the protein can suppress follicle stimulating hormone (FSH) but not luteinizing hormone (EACH), thyroid stimulating hormone or prolactin in an in vitro bioassay system, and the protein can be labeled with radioactive iodine. In addition to the forgoing, there is also provided a method for isolating and purifying inhibin from mammalian ovarian follicular fluid, characterized by one or more gel permeation chromatography steps; reversed-phase high performance liquid chromatography steps; preparative polyacrylamide gel electrophoresis steps; and electrophoretic elution of the purified inhibin.
5364947 PROCESS F O R SEPARATING CEPHALOMANNINE FROM T A X O L USING O Z O N E A N D WATER-SOLUBLE HYDRAZINES OR H Y D R A Z I D E S Murray Christopher K; Beckvermit Jeffrey T; Anziano Dominick - Hauser Chemical Research Inc A process for separating non-oxidizable compounds from a mixture containing at least one oxidizable compound. The mixture is contacted with ozone to oxidize oxidizable compounds to form oxidized compounds which are then converted to water-soluble hydrazones, followed by separation of the hydrazones from the mixture using precipitation, liquid/liquid extraction, chromatography, etc.
5366730 STABILIZED C O M P O S I T I O N S HAVING H U M A N TISSUE TYPE PLASMINOGEN ACTIVATOR ENZYMATIC ACTIVITY Kohnert Ulrich; Rudolph Rainer, Habach, FEDERAL REPUBLIC OF GERMANY Boehringer Mannheim GmbH Pharmaceutical preparation of a protein with t-PA activity with an enzymatic activity of at least 0.25 MU/ml. and a pH value of 4.5 to 9 which contains a substance of the group citric acid, ascorbic acid, 2-oxoglutaric acid, fumaric acid, Tris and EDTA
101
in a concentration of at least 0.2 mole/l., as well as a medicament based on a protein with t-PA activity and processes for its preparation.
5366861 IlVIMUNOASSAY AND R E A G E N T KIT USED T H E R E F O R Hosoda Kenji; Kubota Takahar; Honda Hitomi; Suzuki Hideaki - Teijin Limited An immunoassay method performed in solution wherein a protein having an average molecular weight of 16,000 to 50,000 and an isoelectric point of 1.0 to 5.0 or a mixture containing the same is permitted to exist as the antigen-antibody reaction controller in the immunoreaction solution, and the final concentration of the antigen-antibody controller in the immunoreaction solution is controlled to 0.02 to 0.9% by weight, and a reagent kit to be used for an immunoassay containing the above antigen-antibody reaction controller at a final concentration of 0.02 to 0.9% by weight in the immunoreaction solution, as a part of the constituents thereof.
5366862 METHOD FOR GENERATING A N D SCREENING USEFUL PEPTIDES Venton Duane; Hopfinger Anton J; Le Breton Guy - Receptor Laboratories Inc The invention allows the generation and screening of a large population of peptides for the presence of peptides which bind a particular macromolecule or macromolecular complex with high affinity, and further allows the favored net synthesis of analyzable quantities of such peptides, by using as the trap a macromolecule or macromolecular complex for which binding of the peptide is desired. The starting mixture is preferably spiked with a peptide having some affinity for the target macromolecule so that mutation of the spike or lead peptide is favored. The development of improved binding peptides through scrambling may be dynamically monitored by initially binding the target with an insolubilized ligand, and then looking for an increase in the concentration of the target in the soluble phase as a result of the displacement of the reference ligand by scrambled peptides.
5364947 PROCESS F O R SEPARATING CEPHALOMANNINE FROM T A X O L USING O Z O N E A N D WATER-SOLUBLE HYDRAZINES OR H Y D R A Z I D E S Murray Christopher K; Beckvermit Jeffrey T; Anziano Dominick - Hauser Chemical Research Inc A process for separating non-oxidizable compounds from a mixture containing at least one oxidizable compound. The mixture is contacted with ozone to oxidize oxidizable compounds to form oxidized compounds which are then converted to water-soluble hydrazones, followed by separation of the hydrazones from the mixture using precipitation, liquid/liquid extraction, chromatography, etc.
5366730 STABILIZED C O M P O S I T I O N S HAVING H U M A N TISSUE TYPE PLASMINOGEN ACTIVATOR ENZYMATIC ACTIVITY Kohnert Ulrich; Rudolph Rainer, Habach, FEDERAL REPUBLIC OF GERMANY Boehringer Mannheim GmbH Pharmaceutical preparation of a protein with t-PA activity with an enzymatic activity of at least 0.25 MU/ml. and a pH value of 4.5 to 9 which contains a substance of the group citric acid, ascorbic acid, 2-oxoglutaric acid, fumaric acid, Tris and EDTA
101
in a concentration of at least 0.2 mole/l., as well as a medicament based on a protein with t-PA activity and processes for its preparation.
5366861 IlVIMUNOASSAY AND R E A G E N T KIT USED T H E R E F O R Hosoda Kenji; Kubota Takahar; Honda Hitomi; Suzuki Hideaki - Teijin Limited An immunoassay method performed in solution wherein a protein having an average molecular weight of 16,000 to 50,000 and an isoelectric point of 1.0 to 5.0 or a mixture containing the same is permitted to exist as the antigen-antibody reaction controller in the immunoreaction solution, and the final concentration of the antigen-antibody controller in the immunoreaction solution is controlled to 0.02 to 0.9% by weight, and a reagent kit to be used for an immunoassay containing the above antigen-antibody reaction controller at a final concentration of 0.02 to 0.9% by weight in the immunoreaction solution, as a part of the constituents thereof.
5366862 METHOD FOR GENERATING A N D SCREENING USEFUL PEPTIDES Venton Duane; Hopfinger Anton J; Le Breton Guy - Receptor Laboratories Inc The invention allows the generation and screening of a large population of peptides for the presence of peptides which bind a particular macromolecule or macromolecular complex with high affinity, and further allows the favored net synthesis of analyzable quantities of such peptides, by using as the trap a macromolecule or macromolecular complex for which binding of the peptide is desired. The starting mixture is preferably spiked with a peptide having some affinity for the target macromolecule so that mutation of the spike or lead peptide is favored. The development of improved binding peptides through scrambling may be dynamically monitored by initially binding the target with an insolubilized ligand, and then looking for an increase in the concentration of the target in the soluble phase as a result of the displacement of the reference ligand by scrambled peptides.